AIM ImmunoTech Says Overall Survival Analysis In Phase 2 Pancreatic Cancer Trial To Begin In Q3 2027; Reiterates Q1 2027 Topline Data

Benzinga Newsdesk www.benzinga.com Neutral 78.3%